Lineage Cell Therapeutics (LCTX) News
NYSE: LCTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
0.7719-0.0481 (-5.87%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LCTX news summary
We found 4 recent headlines mentioning Lineage Cell Therapeutics (LCTX): 0 in the past week and 4 in the past 30 days, most often from Business Wire, Nasdaq. LCTX is making an outsized move today, down 5.87% at $0.7719, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Lineage (LCTX) Q3 2026 Earnings Call Transcript", was published by Nasdaq on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Lineage Cell Therapeutics headlines
- Lineage (LCTX) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaqLCTX, WSO.B
- Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateCARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Q3 2026 Earnings ReleaseBusiness Wire
- Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington’s DiseaseCARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic,…Business Wire
- Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company novel, allogeneic, “off…Business Wire